DelveInsight’s “Food Allergy Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Food Allergy pipeline landscape. It covers the Food Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Food Allergy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Food Allergy Pipeline? Click here to explore the therapies and trials making headlines @ Food Allergy Pipeline Outlook Report
Key Takeaways from the Food Allergy Pipeline Report
- On 04 November 2025, DBV Technologies conducted a Phase 3 study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).
- DelveInsight’s Food Allergy Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Food Allergy treatment.
- The leading Food Allergy Companies, such as DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others.
- Promising Food Allergy Therapies such as Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib and others.
Want to know which companies are leading innovation in Food Allergy? Dive into the full pipeline insights @ Food Allergy Clinical Trials Assessment
The Food Allergy Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Food Allergy Pipeline Report also highlights the unmet needs with respect to the Food Allergy.
Food Allergy Overview
Food allergies are adverse health effects resulting from a specific immune response that occurs reproducibly on exposure to a given food. These immune responses can range from mild to severe, potentially affecting the skin, gastrointestinal tract, respiratory, and cardiovascular systems. Food allergies are distinct from food intolerances, which do not involve the immune system and are generally less severe. The prevalence of food allergies has been rising, especially in developed countries, with an estimated 5-8% of children and 1-2% of adults affected worldwide.
Food Allergy Emerging Drugs Profile
- Viaskin Peanut: DBV Technologies
Viaskin Peanut (DBV712) is the novel product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. The drug is currently being investigated in the Registration stage of development for the treatment of peanut allergy.
- PVX-108: Aravax
PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once per month, therapy is designed to precisely induce tolerance to peanut protein without the safety concerns constraining the use of the only registered therapy which uses natural extracts from peanuts. The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis. Previously, a randomized, double-blind, placebo-controlled Phase I trial in 66 peanut-allergic adults (AVX-001) showed no evidence of adverse events of clinical concern. Additionally, ex vivo studies providing a surrogate measure of safety (basophil activation) in 185 peanut-allergic blood donors confirmed a lack of basophil reactivity to PVX108 in contrast to peanut extract. These data demonstrate that PVX108 has a highly favorable safety profile for treatment of peanut allergic patients, including those with severe allergy. The drug is currently being investigated in the Phase II stage of development for the treatment of peanut allergy.
- INT301: Intrommune Therapeutics
INT301 is an investigational oral mucosal immunotherapy (OMIT) product developed by Intrommune Therapeutics for the treatment of peanut allergy. It is a toothpaste-based formulation designed for daily use, delivering allergen proteins directly to the immune system via the oral mucosa to induce desensitization. Unlike traditional oral immunotherapy (OIT), INT301 aims to reduce allergic reactions with improved safety and convenience. The product is currently in clinical development. The drug is currently being investigated in the Phase I stage of development for the treatment of peanut allergy.
If you’re tracking ongoing Food Allergy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Food Allergy Treatment Drugs
The Food Allergy Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Food Allergy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Food Allergy Treatment.
- Food Allergy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Food Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Food Allergy market.
Food Allergy Companies
DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others.
Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Food Allergy Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
From emerging drug candidates to competitive intelligence, the Food Allergy Pipeline Report covers it all – check it out now @ Food Allergy Market Drivers and Barriers, and Future Perspectives
Scope of the Food Allergy Pipeline Report
- Coverage- Global
- Food Allergy Companies- DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others.
- Food Allergy Therapies- Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib and others.
- Food Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Food Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the Food Allergy Treatment landscape in this detailed analysis @ Food Allergy Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Food Allergy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Food Allergy– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Viaskin Peanut: DBV Technologies
- Mid Stage Products (Phase II)
- PVX-108: Aravax
- Early Stage Products (Phase I)
- INT301: Intrommune Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Food Allergy Key Companies
- Food Allergy Key Products
- Food Allergy- Unmet Needs
- Food Allergy- Market Drivers and Barriers
- Food Allergy- Future Perspectives and Conclusion
- Food Allergy Analyst Views
- Food Allergy Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/food-allergy-pipeline-insight